Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials

Ronald F. Van Vollenhoven, Paul Emery, Clifton O. Bingham, Edward C. Keystone, Roy Fleischmann, Daniel E. Furst, Katherine Macey, Marianne Sweetser, Ariella Kelman, Rao Ravi

Research output: Contribution to journalArticlepeer-review


Objective. To evaluate the longterm safety of rituximab in clinical trials in patients with rheumatoid arthritis (RA). Methods. Pooled analysis of safety data, including adverse events (AE) and infections, from patients treated with rituximab in combination with methotrexate in a global clinical trial program. Results. A total of 2578 patients with RA received at least 1 course of rituximab. Safety analyses were based on 5013 patient-years of rituximab exposure. The most frequent AE was infusion-related reactions (25% of patients during the first infusion of Course 1). Less than 1% of infusion-related reactions were considered serious. Rates of AE and serious AE (SAE; 17.85 events/100 patient-yrs, 95% CI 16.72, 19.06) were stable following each course. The overall serious infection rate was 4.31/100 patient-years (95% CI 3.77, 4.92). Infections and serious infections over time remained stable across 5 courses at 4-6 events/100 patient-years. Compared with other patients with RA and with the general US population, there was no increased risk of malignancy. Conclusion. In this longterm safety update in RA clinical trial patients, rituximab remained well tolerated over multiple courses. SAE and infections remained stable over time and by treatment course. The Journal of Rheumatology

Original languageEnglish (US)
Pages (from-to)558-567
Number of pages10
JournalJournal of Rheumatology
Issue number3
StatePublished - Mar 2010


  • Clinical trials
  • Rheumatoid arthritis
  • Rituximab

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials'. Together they form a unique fingerprint.

Cite this